Please share...
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small phase I clinical trial, report researchers at Georgetown University Medical Center in Washington. In addition, the drug, nilotinib (Tasigna(r) by Novartis), led to statistically significant and encouraging changes in toxic proteins linked to disease progression (biomarkers).
Newswise: Latest News
